Identification of New FTLD Genes (FTLD-Exome)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02363062|
Recruitment Status : Unknown
Verified August 2016 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : February 13, 2015
Last Update Posted : August 29, 2017
The major objective of the project is to map/identify new loci/genes, by a combination of whole exome sequencing and genome-wide linkage in autosomal dominant FTLD families excluded for known mutations.
Several secondary goals will be attained in the course of during the project:
For each novel gene identified in this project, we will determine the spectrum of mutations, evaluate their frequency and characterize the associated phenotypes. This will allow us to establish genotype-phenotype correlations in a large number of families, which will improve the nosology of these disorders and the diagnostic procedures;
|Condition or disease|
|Frontotemporal Lobar Degeneration|
Background and justification of the research. In France, 6,000 to 8,000 patients are affected by frontotemporal lobar degeneration (FTLD). FTLD are degenerative dementias related to Alzheimer's disease, characterized by behavioural, language and cognitive disorders beginning in the sixth decade. The genetic forms of FTLD are frequent (30-50% of the patients), but the genes responsible for 30-40% of familial FTLD are still unknown. At present, no molecular diagnosis can be proposed for 30% of the FTLD families and patients, for which the responsible genes are still unknown. No presymptomatic testing can be proposed either to at-risk relatives in these families.
- The principal objective of this proposal is to identify one or several genes responsible for FTLD.
The secondary objectives are to:
- evaluate the relative frequency of identified genes;
- describe the phenotypes associated with the mutations in these genes;
- establish phenotype-genotype correlations in order to improve the diagnostic procedures and strategies;
- develop new genetic diagnostic analyses in the near future.
Project The patients will be recruited in three hospitals (Paris Salpetriere, Limoges, Lille). These three centers are partners of a national clinico-genetic network of 20 french centers experts in FTLD/FTLD-ALS, coordinated by Dr. I Le Ber. The participants in this network have collaborated for the last 15 years, and have already recruited over 1,000 patients with FTLD. Sequencing of known genes in these families allowed the identification of 150 families with an autosomal dominant form of FTLD not associated with a known mutation. Through the network, we aim to recruit 400 new patients with FTLD during the 4 years of the project. This estimation is based on the annual recruitment of the network during the last two years.
In this project, the 30 most informative families will be extended (440 patients and relatives sampled).
The combination of whole exome sequencing with genetic linkage studies in FTLD families without known mutations, and the large number of families included in this project, are two major points that should lead to the identification of several new genes. When causative genes are identified, we will establish the frequencies of mutations, extend the mutational spectrum, describe the clinical phenotypes and establish phenotype-genotype correlations. Genetic parameters such as penetrance will be analyzed.
|Study Type :||Observational|
|Estimated Enrollment :||440 participants|
|Official Title:||Identification of New Genes Causing Frontotemporal Lobar Degeneration by Whole Exome Sequencing and Characterization of the Associated Phenotypes|
|Actual Study Start Date :||February 2, 2015|
|Estimated Primary Completion Date :||February 1, 2019|
|Estimated Study Completion Date :||February 1, 2019|
- whole exome sequencing [ Time Frame: Day 1 ]genes responsible for FTLD /Blood samples will be collected by a nurse, during a single consultation or hospitalization
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363062
|Contact: Isabelle LE BER, MD, PhD||(+33) 01 57 27 46 email@example.com|
|Pitié Salpetriere Hospital||Recruiting|
|Paris, France, 75013|
|Contact: Isabelle LE BER|
|Principal Investigator:||Isabelle LE BER, MD, PhD||Assistance Publique - Hôpitaux de Paris|